TELIX PHARMACEUTICALS
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer.
TELIX PHARMACEUTICALS
Industry:
Biotechnology
Founded:
2015-11-01
Address:
Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.telixpharma.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
494.87 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Google Maps
Similar Organizations
Abogen Biosciences
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based RNA and DNA therapeutics.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2024-03-04 | ARTMS | ARTMS acquired by Telix Pharmaceuticals | N/A |
| 2024-02-09 | IsoTherapeutics Group | IsoTherapeutics Group acquired by Telix Pharmaceuticals | 13 M USD |
| 2023-11-13 | QSAM Biosciences | QSAM Biosciences acquired by Telix Pharmaceuticals | N/A |
| 2023-04-26 | Dedicaid | Dedicaid acquired by Telix Pharmaceuticals | N/A |
| 2022-11-14 | Optimal Tracer | Optimal Tracer acquired by Telix Pharmaceuticals | N/A |
| 2020-11-30 | TheraPharm | TheraPharm acquired by Telix Pharmaceuticals | 33 M AUD |
| 2018-11-26 | Advanced Nuclear Medicine Ingredients | Advanced Nuclear Medicine Ingredients acquired by Telix Pharmaceuticals | 5.15 M EUR |
| 2018-09-11 | Atlab Pharma | Atlab Pharma acquired by Telix Pharmaceuticals | N/A |
Investors List
Australian Government
Australian Government investment in Grant - Telix Pharmaceuticals
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2023-11-12 | Mauna Kea Technologies | Telix Pharmaceuticals investment in Post-IPO Equity - Mauna Kea Technologies | 6 M EUR |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-12-04 | Telix Announces Executive Leadership Appointments |
| 2022-07-11 | Telix Pharmaceuticals names CEO of U.S. operations |
| 2021-08-31 | Michael Didocha Joins Telix as Chief Financial Officer, Americas |
Official Site Inspections
http://www.telixpharma.com Semrush global rank: 795.5 K Semrush visits lastest month: 37.25 K
- Host name: 104.19.154.92
- IP address: 104.19.154.92
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Telix Pharmaceuticals"
Our Company - Telix Pharmaceuticals
Many existing therapies for cancer and rare diseases are non-selective, impacting healthy tissue and vital organs while treating the disease. Our radiopharmaceuticals are designed to deliver …See details»
Board & Management - Telix Pharmaceuticals
Our mission is to help patients with cancer live longer with better quality livesSee details»
Contact - Telix Pharmaceuticals
KYOTO 2921 Stockton Blvd #1710, Sacramento, CA 95817, United States Email: [email protected]See details»
About Telix | 2024 Annual Report - annualreport.telixpharma.com
We are a global, commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical …See details»
2024 Annual Report
2024 Annual Report 2024 was a transformative year, in which we laid the foundation for the next phase of growth while continuing to deliver a strong commercial and financial performance.See details»
Telix Pharmaceuticals - Crunchbase Company Profile
Telix Pharmaceuticalsis a clinical-stage biotechnology company focused on the development of diagnostic and therapeutic products.See details»
Telix Pharmaceuticals (TLX) Company Profile & Description
Jul 23, 2025 Company profile for Telix Pharmaceuticals Limited (TLX) stock, with a description, list of executives, contact details and other key facts.See details»
A message from the Chair | 2024 Annual Report
Telix is now a global radiopharmaceutical company with a specialist commercial organization, a deep pipeline of late-stage and next-generation theranostic programs, and global …See details»
Company directory | 2024 Annual Report
[email protected] www.telixpharma.com Australian Business Number 85 616 620 369 Securities Exchange Listing Australian Securities Exchange ASX Code: TLX Nasdaq Global …See details»
Telix Pharmaceuticals Limited Management Team | Org Chart
Telix Pharmaceuticals Limited employs 586 employees. The Telix Pharmaceuticals Limited management team includes David Cade (CEO Telix Asia Pacific), Rachel Haverfield (Assistant …See details»
Telix Announces Reorganisation to Deliver on Strategic Priorities
Telix today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led …See details»
Investor Relations - Telix Pharmaceuticals Limited
Jul 9, 2025 Telix Pharmaceuticals Limited Investor relations (IR) website contains information about our business for stockholders, potential investors, and financial analysts.See details»
Telix Pharmaceuticals (ASX:TLX) Company Profile & Description
5 days ago Company profile for Telix Pharmaceuticals Limited (ASX:TLX) with a description, list of executives, contact details and other key facts.See details»
A message from the CEO | 2024 Annual Report
By the end of 2025, we expect Telix to look like a different company yet again. Our metamorphosis is well underway, as we become a globally active, multi-product company, with …See details»
Telix Pharmaceuticals Org Chart + Executive Team
The org chart of Telix Pharmaceuticals contains its 36 main executives like Christian Behrenbruch, Darren Smith and Darren Patti.See details»
Governance at a glance | 2024 Annual Report
A detailed matrix of Board skills is available in our 2024 Corporate Governance Statement, available at ir.telixpharma.com/governance/documents-charters.See details»
Telix Announces Board Renewal - ir.telixpharma.com
Feb 26, 2025 Telix Announces Board Renewal Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 26 February 2025. Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, …See details»
Telix Pharmaceuticals (TLPPF) Company Profile & Description
4 days ago Company profile for Telix Pharmaceuticals Limited (TLPPF) with a description, list of executives, contact details and other key facts.See details»
Careers - Telix Pharmaceuticals
You will be supporting the international roll-out of our approved prostate cancer imaging agent, and helping us to advance our portfolio of late clinical-stage products that addresses …See details»
Telix Reports $204M Revenue, Up 63% YOY - telixpharma.com
Jul 22, 2025 Q2 2025 unaudited group revenue of approximately $204 million, up 63% year-over-year. FY 2025 revenue guidance of $770 million to $800 million is reaffirmed. Gozellix® …See details»